Author: Wang, Shujing; Liu, Huiqin; Zhang, Xinyi; Qian, Feng
Title: Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies Cord-id: sgy2wh8m Document date: 2015_5_6
ID: sgy2wh8m
Snippet: Most pathogens initiate their infections at the human mucosal surface. Therefore, mucosal vaccination, especially through oral or intranasal administration routes, is highly desired for infectious diseases. Meanwhile, protein-based antigens provide a safer alternative to the whole pathogen or DNA based ones in vaccine development. However, the unique biopharmaceutical hurdles that intranasally or orally delivered protein vaccines need to overcome before they reach the sites of targeting, the rel
Document: Most pathogens initiate their infections at the human mucosal surface. Therefore, mucosal vaccination, especially through oral or intranasal administration routes, is highly desired for infectious diseases. Meanwhile, protein-based antigens provide a safer alternative to the whole pathogen or DNA based ones in vaccine development. However, the unique biopharmaceutical hurdles that intranasally or orally delivered protein vaccines need to overcome before they reach the sites of targeting, the relatively low immunogenicity, as well as the low stability of the protein antigens, require thoughtful and fine-tuned mucosal vaccine formulations, including the selection of immunostimulants, the identification of the suitable vaccine delivery system, and the determination of the exact composition and manufacturing conditions. This review aims to provide an up-to-date survey of the protein antigen-based vaccine formulation development, including the usage of immunostimulants and the optimization of vaccine delivery systems for intranasal and oral administrations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13238-015-0164-2) contains supplementary material, which is available to authorized users.
Search related documents:
Co phrase search for related documents- acute sars cov respiratory syndrome coronavirus and adaptive immune system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute sars cov respiratory syndrome coronavirus and adhesion integrin: 1, 2
- acute sars cov respiratory syndrome coronavirus and adjuvant alum: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute sars cov respiratory syndrome coronavirus and adjuvant antigen: 1, 2, 3, 4, 5, 6
- acute sars cov respiratory syndrome coronavirus and adjuvant antigen delivery: 1
- acute sars cov respiratory syndrome coronavirus and adjuvant cpg: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute sars cov respiratory syndrome coronavirus and adjuvant ctb: 1
- acute sars cov respiratory syndrome coronavirus and adjuvant free: 1
- acute sars cov respiratory syndrome coronavirus and adjuvant mucosal vaccine: 1
- acute sars cov respiratory syndrome coronavirus and adjuvant protein antigen: 1
- acute sars cov respiratory syndrome coronavirus and administration formulation: 1, 2, 3
- acute sars cov respiratory syndrome coronavirus and administration formulation route: 1
- acute sars cov respiratory syndrome coronavirus and administration route: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute sars cov respiratory syndrome coronavirus and live viral vector: 1, 2, 3, 4, 5, 6
- acute sars cov respiratory syndrome coronavirus and loaded protein: 1, 2
- acute sars cov respiratory syndrome coronavirus and loading capacity: 1
- acute sars cov respiratory syndrome coronavirus and loading efficiency: 1
- acute sars cov respiratory syndrome coronavirus and local initiation: 1
- acute sars cov respiratory syndrome coronavirus and local mucosal: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date